PSMA ADC

Progenics Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	PSMA ADC
Sponsor	Progenics Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (PHASE1)
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (PHASE2)
Combination of 68Ga-PSMA PET Data With Magnetic Resonance Spectroscopy Data (MRS) for Evaluating Prostate Cancer (NA)
An Open-label Extension Study of PSMA ADC 2301 in mCRPC (PHASE2)
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) (PHASE2)
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer (PHASE1)
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer (PHASE1)
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PSMA ADC CI brief — competitive landscape report
PSMA ADC updates RSS · CI watch RSS
Progenics Pharmaceuticals, Inc. portfolio CI